Financial institutions' gender balance progress under threat, study shows
By Marc Jones
LONDON (Reuters) -The rise in the number of women holding top jobs at leading financial institutions has slowed over the last year and further progress is under threat as the United States and other countries roll back diversity drives, a new report has shown.
The annual Gender Balance Index published by the London-based OMFIF think tank on Wednesday showed the share of female leaders of central banks, commercial banks and sovereign and pension funds at an all-time high of 16%, although that was "only decimal points higher" than last year.
The share acoss all senior positions was also just one percentage point higher at 32%, while the index, which measures overall gender balance, stood at 42 out of 100, "less than halfway to gender balance".
Diversity efforts face a testing time as the U.S. government under Donald Trump seeks to remove diversity, equity and inclusion programmes from federal agencies and push the private sector to follow suit.
"While the U.S. has been most vocal in this retreat, there is evidence of contagion on a global scale, with institutions in Asia and Europe also rolling back policies," the report said.
There has nevertheless been some progress.
Sovereign funds, which manage a nation's wealth, had the largest year-on-year index score improvement, taking it to 38, double where it was 2021, with progress predominantly driven by emerging economies.
A record 30 women now head central banks and, as a group, the 50 commercial banks in the study also saw their largest index score increase since their inclusion in 2021.
But the pipeline of female talent is thin: the overall share of women in executive C-suite roles increased to 19% from 15%, but almost half of the commercial banks in the index still have no women in their C-suite.
Female CEOs remain also below 15%, with one woman CEO appointed last year against nine new men. The share of women in pension fund C-suite roles also fell to 28% from 31% the previous year.
The modest progress could go into reverse, the report said, noting six of the biggest U.S. banks – Citi, Morgan Stanley, Wells Fargo, Bank of America, Goldman Sachs and JPMorgan – were all cutting their diversity, equity and inclusion programmes.
"Although it is too soon to say what implications this rollback will have on gender balance, given the instability in its pipeline, it is likely that North America may not remain the highest-scoring region in the future," it said.
(Additional Reporting by Simon Jessop; editing by Barbara Lewis)
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
21 minutes ago
- Yahoo
Air India chairman says crash should drive effort to build safer airline
By Aditya Kalra NEW DELHI (Reuters) -Air India's Chairman N. Chandrasekaran on Monday told staff that last week's plane crash that killed at least 271 people should be a catalyst to build a safer airline, urging employees to stay resolute amid any criticism. In a town hall held at the headquarters of the Tata Group-owned airline near New Delhi and attended by 700 staff, Chandrasekaran said the crash was the "most heartbreaking" crisis of his career, a spokesperson told Reuters. "I've seen a reasonable number of crises in my career, but this is the most heartbreaking one," he said, according to a Tata Group spokesperson. "We need to use this incident as an act of force to build a safer airline," Chandrasekaran told the meeting. The Boeing 787-8 Dreamliner with 242 people on board bound for Gatwick Airport south of London began losing height seconds after take-off in Ahmedabad on Thursday, and erupted in a huge fireball as it hit buildings below. All but one on board were declared dead in the world's worst aviation disaster in a decade, and around 30 people died on the ground. The airline and the Indian government are looking at several aspects of the crash, including the plane's engine thrust, flaps, and why the landing gear remained open as the plane took off and then came down. "We need to wait for the investigation ... It's a complex machine, so a lot of redundancies, checks and balances, certifications, which have been perfected over years and years. Yet this happens, so we will figure out why it happens after the investigation," Chandrasekaran, 62, said during the staff meeting. He is also the chairman of the Tata Group conglomerate. The crash poses a new challenge for both Air India which has for years been trying to revamp its ageing fleet, and Boeing, which is trying to rebuild public trust following a series of safety and production crises. After taking the carrier over from the government in 2022, the Tata Group unveiled its investment plans to create a "world-class airline" after years of financial losses, persistent flight delays and poor maintenance under government ownership. On Monday, an Air India Boeing 787-8 Dreamliner plane bound for New Delhi returned to its origin of Hong Kong shortly after takeoff following a technical issue. "It's not easy to face criticisms," Chandrasekaran said. "We are going to get through this. We need to show resilience." In Ahmedabad, dozens of anxious family members have been waiting to collect bodies of relatives killed in the crash, as doctors worked to gather dental samples from the deceased and run identification checks. Only 99 samples have been matched so far, and 64 bodies have been handed over to the families, Rakesh Joshi, Medical Superintendent of a civil hospital in the city, said. Authorities late on Sunday also said both the flight data recorder and cockpit voice recorder have been located and secured, which will be key in the investigation. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
22 minutes ago
- Yahoo
Cresilon Announces International Distribution Agreement for VETIGEL with McCarthy Vet
Revolutionary hemostatic gel for veterinary surgeons available in Canada through leading veterinary supply company NEW YORK, June 16, 2025 /PRNewswire/ -- Cresilon Inc. ("Cresilon"), a Brooklyn-based biotechnology company focused on hemostatic medical device technologies, today announced it has entered into a distribution agreement for VETIGEL® to be sold directly to veterinary surgeons in Canada through McCarthy Vet, a full-service veterinary marketing, supply and distribution company exclusively serving veterinarians in the Canadian animal health industry. VETIGEL, a revolutionary plant-based hemostatic gel that instantly stops and controls bleeding, is now available for veterinarian surgeons across Canada through McCarthy Vet. The agreement with McCarthy Vet, a family-owned and operated company that has exclusively served the Canadian veterinary community for over 60 years, is Cresilon's first veterinary distribution partnership in Canada. "Our partnership with McCarthy Vet will help us provide more veterinary surgeons with an innovative hemostatic gel that significantly improves the standard of care for pets and animals," said VETIGEL National Sales Manager Brittany Boysen. "VETIGEL has been used by thousands of veterinarians around the world and helps veterinary clinics and animal hospitals save time, reduce operating costs, and improve patient outcomes." Since the product's debut in 2021, veterinary surgeons across North America, Europe, and Asia have increasingly used VETIGEL as the fastest and most effective hemostatic agent when treating animals for traumatic wounds and routine and complex surgical procedures, including dental extractions, liver biopsies, tumor and mass removals, cleft palate repairs, and amputations. To date, the plant-based hemostatic gel for veterinary surgeons has been used in more than 60,000 surgical procedures worldwide. As McCarthy Vet expands its portfolio through a new partnership with VETIGEL, the company remains focused on delivering the solutions today's veterinary professionals need most. This collaboration reflects its ongoing promise to bring innovative products to market that offer meaningful clinical value, ease of use, and better outcomes for patients. As a flowable hemostatic gel, VETIGEL offers veterinary surgeons a safe and efficient way to control bleeding across a wide range of surgical procedures and wound geometries. The veterinary hemostatic agent is biocompatible, non-animal derived, and made with an innovative blend of plant polymers that form an instant mechanical barrier to stop bleeding on contact. Once the bleeding is controlled, VETIGEL can be easily removed without disturbing the underlying clot or left in the body to resorb. VETIGEL is supplied in a pre-filled syringe, easy-to-use, and requires no preparation or special storage conditions. For more information about VETIGEL, visit For more information about McCarthy Vet, visit About CresilonCresilon® is a Brooklyn-based biotechnology company that develops, manufactures, and markets hemostatic medical devices utilizing the company's proprietary hydrogel technology. The company's plant-based technology has revolutionized the current standard by stopping bleeding in seconds. The company's current and future product lines target trauma care, biosurgery, and animal health. Cresilon's mission is to save lives. For more information about Cresilon, which was named to Fast Company's annual list of the World's Most Innovative Companies of 2024, ranking No. 1 in the medical devices category, visit About McCarthy VetMcCarthy Veterinary Supplies has proudly served Canadian Veterinarians for over 60 years. McCarthy is committed to bringing clinics the most innovative products, expertise, and service to improve the health of animals, and thereby improve the lives of those who care for them. McCarthy is based in Alberta, Canada, with reps exclusively serving veterinarians in every province from coast to coast. View original content to download multimedia: SOURCE Cresilon
Yahoo
22 minutes ago
- Yahoo
Bracco Imaging and Subtle Medical obtain CE mark for AI-powered MRI software
Italy-based Bracco Imaging and Subtle Medical have obtained an EU CE mark for AiMIFY, a jointly developed software designed to enhance the imaging of contrast MRI brain scans using artificial intelligence (AI). Developed through the application of Bracco's imaging and Subtle's software, clinical evidence has demonstrated that AiMIFY provides contrast enhancement for MRI brain scans up to twice the level typically achieved with a labelled dose of gadolinium-based contrast agents (GBCAs). Consequently, AiMIFY enhances the visualisation of small and poorly enhanced lesions that are critical to the early detection of certain conditions. US-based Subtle Medical's chief product officer, Ajit Shankaranarayanan, points out that in achieving imaging enhancements in contrast MRI scans, whereby a contrast agent is administered to a patient before an MRI is undertaken, the software requires no adjustments to these standard practices. According to the companies, validation data for AiMIFY, which was granted software as a medical device (SaMD) clearance from the US Food and Drug Administration (FDA) in October 2024, has demonstrated the technology's efficacy across diverse patient demographics, pathologies, lesion sizes, scanner vendors, MRI sequences, and acquisition orientations. Radiology platform leader at Bracco Imaging, Sascha Daeuber commented: 'With the CE Mark for AiMIFY, we're taking the next step in our shared mission to deliver innovative, AI-powered solutions that enhance diagnostic precision and support radiologists and patients worldwide." Bracco and Subtle Medical stated that they will now initiate commercialisation activities for AiMIFY in select European markets, with a phased commercial rollout expected between late 2025 and early 2026. According to a 2023 report by GlobalData, the use of AI across healthcare is burgeoning, with the market forecast to reach a valuation of around $19bn by 2027. Radiology has emerged as one of the most common areas in which AI is being applied – as a means to drive efficiencies and alleviate clinician burnout. In a recent report by KPMG on AI's impact on healthcare, 86% of healthcare professionals expressed their belief that AI adoption would give their organisation a competitive edge over those who did not. "Bracco Imaging and Subtle Medical obtain CE mark for AI-powered MRI software" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.